BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 36961457)

  • 21. Racial and ethnic disparities in emergency department-initiated buprenorphine across five health care systems.
    Holland WC; Li F; Nath B; Jeffery MM; Stevens M; Melnick ER; Dziura JD; Khidir H; Skains RM; D'Onofrio G; Soares WE
    Acad Emerg Med; 2023 Jul; 30(7):709-720. PubMed ID: 36660800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interrupted Time Series of User-centered Clinical Decision Support Implementation for Emergency Department-initiated Buprenorphine for Opioid Use Disorder.
    Holland WC; Nath B; Li F; Maciejewski K; Paek H; Dziura J; Rajeevan H; Lu CC; Katsovich L; D'Onofrio G; Melnick ER
    Acad Emerg Med; 2020 Aug; 27(8):753-763. PubMed ID: 32352206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
    Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
    JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD).
    Khatri UG; Lee K; Lin T; D'Orazio JL; Patel MS; Shofer FS; Perrone J
    J Med Toxicol; 2022 Jul; 18(3):205-213. PubMed ID: 35415804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
    Lane BH; Lyons MS; Stolz U; Ancona RM; Ryan RJ; Freiermuth CE
    Am J Emerg Med; 2021 Feb; 40():173-176. PubMed ID: 33243535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a Peer-Led Behavioral Intervention for Emergency Department Patients at High Risk of Fatal Opioid Overdose: A Randomized Clinical Trial.
    Beaudoin FL; Jacka BP; Li Y; Samuels EA; Hallowell BD; Peachey AM; Newman RA; Daly MM; Langdon KJ; Marshall BDL
    JAMA Netw Open; 2022 Aug; 5(8):e2225582. PubMed ID: 35943744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
    Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
    JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.
    Tilhou AS; Dague L; Saloner B; Beemon D; Burns M
    JAMA Health Forum; 2022 Mar; 3(3):e220093. PubMed ID: 35977284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?
    Medicaid Outcomes Distributed Research Network
    J Subst Abuse Treat; 2022 Nov; 142():108807. PubMed ID: 35649885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.
    Treitler P; Nowels M; Samples H; Crystal S
    JAMA Netw Open; 2023 May; 6(5):e2312030. PubMed ID: 37145594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoption of Emergency Department-Initiated Buprenorphine for Patients With Opioid Use Disorder: Secondary Analysis of a Cluster Randomized Trial.
    Gao E; Melnick ER; Paek H; Nath B; Taylor RA; Loza AJ
    JAMA Netw Open; 2023 Nov; 6(11):e2342786. PubMed ID: 37948075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H; Williams AR; Olfson M; Crystal S
    J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities.
    Tassey TE; Ott GE; Alvanzo AAH; Peirce JM; Antoine D; Buresh ME
    J Subst Abuse Treat; 2022 Dec; 143():108895. PubMed ID: 36215913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.